Imipenem Cilastatine Sun

Imipenem/cilastatin, the active ingredient in Imipenem Cilastatine Sun, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections such as intra‑abdominal infections, pneumonia, urinary tract infections, skin and soft‑tissue infections, and septicemia in hospitalized patients. GNH USA supplies Imipenem Cilastatine Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens and reduces morbidity. Complicated urinary tract infections: provides rapid bacterial clearance in resistant Gram‑negative infections. Skin and soft‑tissue infections: treats severe cellulitis and necrotizing infections caused by susceptible organisms. Community‑acquired and hospital‑acquired bacterial pneumonia: offers coverage against resistant Streptococcus pneumoniae and Gram‑negative pathogens. Septicemia: delivers bactericidal activity in bloodstream infections caused by susceptible bacteria.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional episodes after infusion. - Headache: transient and usually resolves. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated diarrhea that can be severe. - Thrombophlebitis: inflammation at the infusion site. - Renal toxicity: rare acute kidney injury. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Before initiating therapy, consider the following precautions: - Renal function: adjust dosage in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor closely in patients with a history of seizures or CNS disorders. - Drug interactions: review concomitant medications that may lower seizure threshold. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at below 25°C: keep in the original container, protect from moisture and light.

Imipenem/cilastatin may interact with several drugs; monitoring is advised.

Major Interactions (Avoid): - Valproic acid: co‑administration can reduce valproate levels, increasing seizure risk. - Cytotoxic chemotherapy agents: may potentiate neurotoxicity when given together.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may increase the risk of nephrotoxicity. - Probenecid: can raise plasma concentrations of imipenem. - Antacids containing magnesium or aluminum: may affect infusion site tolerance, though impact is minimal with IV administration.